| Symbol | KRBPQ |
|---|---|
| Name | KIROMIC BIOPHARMA, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 77054 United States TX 7707 Fannin Suite 140 |
| Telephone | (832) 968-4888 |
| Fax | — |
| — | |
| Website | https://kiromic.com/ |
| Incorporation | US |
| Incorporated On | 2015 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Whitley Penn - Fort Worth, Texas (USA); |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001792581 |
| Description | Kiromic BioPharma, Inc. is a clinical stage, fully integrated biotherapeutics company formed under the Texas Business Organizations Code in December 2012. The Company is an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. Our end-to-end approach consists of target discovery and validation, product development, and on-site current good manufacturing practices ("cGMP"), which we believe will allow us to leverage a new framework for the next generation of cell therapies. Additional info from OTC: |
No news found.